Steroid-Refractory Acute GVHD: Lack of Long-Term Improved Survival Using New Generation AnticytokineTreatment

Biology of Blood and Marrow Transplantation

Volumn 18, Issue 3, 2012, Pages 406-413

  Xhaard, Aliénor ^a   Rocha, Vanderson ^a   Bueno, Benjamin ^a   de Latour, Régis Peffault ^a   Lenglet, Julien ^a   Petropoulou, Anna ^a   Rodriguez Otero, Paula ^a   Ribaud, Patricia ^a   Porcher, Raphael ^b   Socié, Gérard ^a,b   Robin, Marie ^a  

^a SAINT LOUIS HOSPITAL   (France)

^b INSERM   (France)

Author keywords

Anticytokines; Infection; Steroid refractory graft versus host disease

Indexed keywords

BUSULFAN; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; ETANERCEPT; FLUDARABINE; INOLIMOMAB; MELPHALAN; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE LEUKEMIA; ADOLESCENT; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BACTERIAL INFECTION; BACTERIAL PNEUMONIA; CHILD; CYTOMEGALOVIRUS INFECTION; DRUG COST; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HUMAN; LIVER; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MYCOSIS; MYELODYSPLASTIC SYNDROME; OBSERVATIONAL STUDY; OVERALL SURVIVAL; PRESCHOOL CHILD; SCHOOL CHILD; STEROID REFRACTORY ACUTE GRAFT VERSUS HOST DISEASE; SURVIVAL; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS INFECTION; WHOLE BODY RADIATION;

ACUTE DISEASE; ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; CYTOKINES; DRUG RESISTANCE; GRAFT VS HOST DISEASE; HUMANS; MALE; MIDDLE AGED; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 84856949531     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2011.06.012     Document Type: Article

References (30)

1. Robin M., Porcher R., de Castro R., et al. Initial liver involvement in acute GVHD is predictive for nonrelapse mortality. Transplantation 2009, 88:1131-1136.
2. Deeg H.J. How I treat refractory acute GVHD. Blood 2007, 109:4119-4126.
3. Bay J.O., Dhedin N., Goerner M., et al. Inolimomab in steroid-refractory acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation: retrospective analysis and comparison with other interleukin-2 receptor antibodies. Transplantation 2005, 80:782-788.
4. Lee S.J., Zahrieh D., Agura E., et al. Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trial. Blood 2004, 104:1559-1564.
5. Couriel D., Saliba R., Hicks K., et al. Tumor necrosis factor-alpha blockade for the treatment of acute GVHD. Blood 2004, 104:649-654.
6. Perales M.A., Ishill N., Lomazow W.A., et al. Long-term follow-up of patients treated with daclizumab for steroid-refractory acute graft-vs-host disease. Bone Marrow Transplant 2007, 40:481-486.
7. Przepiorka D., Kernan N.A., Ippoliti C., et al. Daclizumab,a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease. Blood 2000, 95:83-89.
8. Funke V.A., de Medeiros C.R., Setubal D.C., et al. Therapy for severe refractory acute graft-versus-host disease with basiliximab, a selective interleukin-2 receptor antagonist. Bone Marrow Transplant 2006, 37:961-965.
9. Srinivasan R., Chakrabarti S., Walsh T., et al. Improved survival in steroid-refractory acute graft versus host disease after non-myeloablative allogeneic transplantation using a daclizumab-based strategy with comprehensive infection prophylaxis. Br J Haematol 2004, 124:777-786.
10. Massenkeil G., Rackwitz S., Genvresse I., Rosen O., Dorken B., Arnold R. Basiliximab is well tolerated and effective in the treatment of steroid-refractory acute graft-versus-host disease after allogeneic stem cell transplantation. Bone Marrow Transplant 2002, 30:899-903.
11. Miano M., Cuzzubbo D., Terranova P., et al. Daclizumab as useful treatment in refractory acute GVHD: a paediatric experience. Bone Marrow Transplant 2009, 43:423-427.
12. Willenbacher W., Basara N., Blau I.W., Fauser A.A., Kiehl M.G. Treatment of steroid refractory acute and chronic graft-versus-host disease with daclizumab. Br J Haematol 2001, 112:820-823.
13. Bordigoni P., Dimicoli S., Clement L., et al. Daclizumab, an efficient treatment for steroid-refractory acute graft-versus-host disease. Br J Haematol 2006, 135:382-385.
14. Ho V.T., Zahrieh D., Hochberg E., et al. Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Blood 2004, 104:1224-1226.
15. Deeg H.J., Blazar B.R., Bolwell B.J., et al. Treatment of steroid-refractory acute graft-versus-host disease with anti-CD147 monoclonal antibody ABX-CBL. Blood 2001, 98:2052-2058.
16. Przepiorka D., Weisdorf D., Martin P., et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995, 15:825-828.
17. Glucksberg H., Storb R., Fefer A., et al. Clinical manifestations ofgraft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974, 18:295-304.
18. Kalbeisch J., Prentice R. The Statistical Analysis of Failure Time Data 1980, Wiley, New York.
19. Prentice R., Kalbeisch J., Peterson A., Flournoy N., Farewell V., Breslow N. The analysis of failure times in the presence of competing risks 1978. Biometrics 1978, 34:541-554.
20. Grambsch P., Therneau T. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 1994, 81:515-556.
21. Vittingho E., McCulloch C. Relaxing the rule of ten events per variable in logistic and Cox regression. Am J Epidemiol 2007, 165:710-718.
22. Ederer F., Axtell L., Cutler S. The relative survival rate: a statistical methodology. Natl Cancer Inst Monogr 1961, 6:101-121.
23. Patriarca F., Sperotto A., Damiani D., et al. Infliximab treatment for steroid-refractory acute graft-versus-host disease. Haematologica 2004, 89:1352-1359.
24. Furlong T., Martin P., Flowers M.E., et al. Therapy with mycophenolate mofetil for refractory acute and chronic GVHD. Bone Marrow Transplant 2009, 44:739-748.
25. Pidala J., Kim J., Perkins J., et al. Mycophenolate mofetil for the management of steroid-refractory acute graft vs. host disease. Bone Marrow Transplant 2010, 45:919-924.
26. Alousi A.M., Weisdorf D.J., Logan B.R., et al. Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network. Blood 2009, 114:511-517.
27. Martin P.J., Schoch G., Fisher L., et al. A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment. Blood 1990, 76:1464-1472.
28. Martin P.J., Schoch G., Fisher L., et al. A retrospective analysis of therapy for acute graft-versus-host disease: secondary treatment. Blood 1991, 77:1821-1828.
29. Galloway J.B., Hyrich K.L., Mercer L.K., et al. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology (Oxford) 2011, 50:124-131.
30. Faraci M., Lanino E., Morreale G., et al. Bacteremias and invasive fungal diseases in children receiving etanercept for steroid-resistant acute GVHD. Bone Marrow Transplant 2011, 46:159-160.